<DOC>
	<DOCNO>NCT01422499</DOCNO>
	<brief_summary>The aim study define dose recommendation vorinostat pediatric oncology , determine pharmacokinetics vorinostat child , determine response rate , safety feasibility .</brief_summary>
	<brief_title>Vorinostat Children</brief_title>
	<detailed_description>Relapsed progressive solid tumor leukemias poor prognosis child despite intense multimodal treatment protocol involve polychemotherapy , surgery , radiation . Therefore , innovative treatment strategy target specific molecular mechanism urgently require . A novel class compound promising anti-tumoral activity histone deacetylase ( HDAC ) -inhibitors . HDACs key enzyme involve regulation chromatin-structure function several protein , aberrant activity HDACs find many cancer cell . Pharmacological inhibition HDACs cause cell cycle arrest , apoptosis , differentiation , inhibition clonogenic growth , anti-angiogenic effect numerous cancer cell . In addition , promise anti-tumoral activity show several pre-clinical pediatric tumor model neuroblastoma , medulloblastoma , glioblastoma , retinoblastoma , rhabdomyosarcoma , osteosarcoma , Ewing 's sarcoma , ATRT , acute lymphoblastic leukemia . Several HDAC inhibitor Phase I-III clinical trial adult patient demonstrate good safety profile promise anti-neoplastic activity . The first compound , suberoylanilide hydroxamic acid ( SAHA , vorinostat , Zolinza ) , recently approve FDA treatment refractory cutaneous T-cell lymphoma . Vorinostat show linear pharmacokinetics , good oral bioavailability broad range anti-tumor activity Phase I clinical trial include 73 adult relapse tumor patient . The determined peak plasma level range 658±439 ng/ml ( correspond 2.5±1.7 µM ) . At concentration , anti-tumoral effect pediatric cancer cell leukemias documented vitro . Furthermore , vorinostat pass blood brain barrier mouse , thus make suitable compound treatment brain tumor . The aim study define dose recommendation vorinostat pediatric oncology , determine pharmacokinetics vorinostat child , determine response rate , safety feasibility . The design open , multicenter Phase I/II trial . Children adolescent ( 3-18 year ) relapse therapy-refractory solid tumor , lymphoma leukemia follow standard treatment protocol pediatric oncology include . 50 patient recruit 2 year . Vorinostat take orally per day outpatient basis dose escalate individual maximum tolerate dose establish . This dose applied 3 month , tumor response evaluate . Patients without progression first response evaluation continue treatment maximum 9 month . After end treatment ( EOT ) follow-up evaluation perform 3 month . Pharmacokinetic study perform plasma , optional cerebrospinal fluid sample . Biomarkers ( BMP4 , IL-6 , IL10 induction follow Vorinostat treatment , basal histone acetylation , HDACs H23B archive tumor sample ) determine correlated treatment response .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<criteria>Children adolescent ( 318 year ) relapse therapyrefractory solid tumor , lymphoma leukemia follow standard firstline relapse protocol pediatric oncology Diagnosis confirm one Pathological , Radiological Study Reference Centers recognize GPOH No simultaneous antineoplastic treatment radiation study 1 month enrolment Sufficient general condition ( Lansky Score &gt; 50 % ) Life expectancy &gt; 3 month Liver enzymes ( ALT AST ) &lt; 5x upper limit normal reference value , bilirubin creatinine &lt; 3x upper limit normal reference value Solid tumor : leukocytes &gt; 2000/µl , thrombocytes &gt; 50.000/µl adequate bone marrow function permit evaluation hematopoietic toxicity No CTC grade 3 4 toxicity previous treatment Normal ECG Written inform consent legal representative patient patient able understand study situation give consent ( must available enrolment trial ) Women childbearing potential agree use adequate contraception abstain heterosexual activity throughout study , start Visit 1 . Sexually active male patient agree use adequate method contraception duration study Solid tumor : measurable disease activity accord RECIST criterion History deep vein thrombosis pulmonary embolism Pregnancy lactation Patient concomitant treatment and/or antineoplastic treatment chemotherapy , immune therapy , differentiation therapy , target therapy , radiation . The use valproic acid prior antiepileptic therapy allow 30day washout period . Prior exposure Histone Deacetylase Inhibitors Known active HBV , HCV HIV infection Patient concomitant treatment amber [ Hypericum perforatum ] , plant extract , vitamin , antioxidative compound Participation clinical trial observation period compete trial , respectively Patient unable swallow vorinostat suspension capsule Patient coumarinderivative anticoagulant Any medication could accentuate know dosedependent adverse effect study drug , instance bone marrow depression QTprolongation</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>pediatric oncology</keyword>
	<keyword>relapse solid tumor</keyword>
	<keyword>lymphoma</keyword>
	<keyword>leukemia</keyword>
	<keyword>vorinostat</keyword>
</DOC>